"The Brazilian Ministry of Health launched on Monday a dengue vaccination campaign aimed at health professionals, with the expectation of protecting 1.2 million workers using the Brazilian vaccine developed by the Butantan Institute, 100 percent produced nationally. Footage shows health professionals administering vaccines at a public health center in Rio de Janeiro. The campaign is part of the National Immunisation Program [PNI] and prioritises primary care professionals, including doctors, nurses, dentists, community health agents, and support staff in public units, aiming to reinforce protection for those who were on the front line against dengue in 2025. "This vaccine is starting to be applied to health professionals here in Rio de Janeiro. So this week we are applying 12,500 doses," said Daniel Soranz, Municipal Health Secretary of Rio de Janeiro. The Butantan-DV vaccine is the world's first single-dose dengue vaccine and was previously authorised by the National Health Surveillance Agency [Anvisa] after clinical trials showed efficacy against all four virus serotypes, representing a milestone in Brazilian medicine. "The vaccine that is manufactured here in Brazil is very important, because we are a reference in terms of vaccines," said Luisa, a health professional. Dengue is a viral disease transmitted by Aedes aegypti mosquitoes, circulating endemically in tropical and subtropical areas, and can cause infections ranging from mild symptoms to severe cases or hemorrhagic dengue. Dengue is not transmitted from person to person, but through infected mosquitoes. According to preliminary statistics from the Ministry of Health, Brazil recorded a significant drop in dengue cases in 2025, with reductions of more than 70 percent compared to 2024, although health authorities continue active surveillance. This decline is attributed to prevention campaigns, mosquito control, improved clinical management, and the arrival of the national vaccine. Authorities expect the campaign to gradually expand to other eligible groups as more doses become available. The overall goal is to reduce hospitalizations and deaths, while strengthening preparedness for future dengue peaks."